Abstract
Population based data on COVID-19 are essential for guiding public policies. We report on the first of a series of planned seroprevalence surveys relying upon on household probabilistic samples of 133 large sentinel cities in Brazil, including 25,025 participants from all 26 states and the Federal District. Seroprevalence of antibodies to SARS-CoV-2, assessed using a lateral flow rapid test, varied markedly across the country’s cities and regions, from below 1% in most cities in the South and Center-West regions to up to 25% in the city of Breves in the Amazon (North) region. Eleven of the 15 cities with the highest seroprevalence were located in the North, including the six cities with highest prevalence which were located along a 2,000 km stretch of the Amazon river. Overall seroprevalence for the 90 cities with sample size of 200 or greater was 1.4% (95% CI 1.3–1.6). Extrapolating this figure to the population of these cities, which represent 25% of the country’s population, led to an estimate of 760,000 cases, as compared to the 104,782 cases reported in official statistics. Seroprevalence did not vary significantly between infancy and age 79 years, but fell by approximately two-thirds after age 80 years. Prevalence was highest among indigenous people (3.7%) and lowest among whites (0.6%), a difference which was maintained when analyses were restricted to the North region, where most indigenous people live. Our results suggest that pandemic is highly heterogenous, with rapid escalation in Brazil’s North and Northeast, and slow progression in the South and Center-West regions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding was provided by the Brazilian Ministry of Health. We acknowledge the support from Instituto Serrapilheira, Pastoral da Crianca, the Brazilian Collective Health Association (ABRASCO) and JBS though the Fazer o Bem Faz Bem initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Interviewers were tested and found to be negative for the virus, and were provided with individual protection equipment that was discarded after visiting each home. Ethical approval was obtained from the Brazilian National Ethics Committee (process number CAAE 30721520.7.1001.5313), with written informed consent from all participants. Positive cases were reported to the municipal COVID-19 surveillance systems.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
prchallal{at}gmail.com; fernandophratwig{at}gmail.com, blhorta{at}gmail.com, victora{at}rockefeller.edu, mariangelafreitassilveira{at}gmail.com, claustru{at}gmail.com, lpvidaletti{at}equidade.org, nneumann{at}pastoraldacrianca.org.br, pellanda{at}ufcspa.edu.br, odirad{at}gmail.com, mnburatt{at}gmail.com, anamene.epi{at}gmail.com, fcbarros.epi{at}gmail.com, abarros.epi{at}gmail.com, cvictora{at}gmail.com
Data Availability
Data will become publicly available upon request from the corresponding author 30 days after publication.
